Mind Medicine Inc
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials… Read more
Market Cap & Net Worth: Mind Medicine Inc (MNMD)
Mind Medicine Inc (NASDAQ:MNMD) has a market capitalization of $1.50 Billion ($1.50 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5916 globally and #3410 in its home market, demonstrating a 9.62% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mind Medicine Inc's stock price $15.38 by its total outstanding shares 97219193 (97.22 Million).
Mind Medicine Inc Market Cap History: 2016 to 2026
Mind Medicine Inc's market capitalization history from 2016 to 2026. Data shows change from $6.40 Billion to $1.50 Billion (-5.93% CAGR).
Index Memberships
Mind Medicine Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.07% | #167 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #694 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.09% | #106 of 263 |
Weight: Mind Medicine Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mind Medicine Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mind Medicine Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MNMD by Market Capitalization
Companies near Mind Medicine Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Mind Medicine Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Mind Medicine Inc Historical Marketcap From 2016 to 2026
Between 2016 and today, Mind Medicine Inc's market cap moved from $6.40 Billion to $ 1.50 Billion, with a yearly change of -5.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.50 Billion | +14.86% |
| 2025 | $1.30 Billion | +92.39% |
| 2024 | $676.65 Million | +90.16% |
| 2023 | $355.82 Million | +66.36% |
| 2022 | $213.88 Million | -89.37% |
| 2021 | $2.01 Billion | -54.75% |
| 2020 | $4.45 Billion | +580.80% |
| 2019 | $653.31 Million | +26.96% |
| 2018 | $514.60 Million | -85.15% |
| 2017 | $3.46 Billion | -45.89% |
| 2016 | $6.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Mind Medicine Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.50 Billion USD |
| MoneyControl | $1.50 Billion USD |
| MarketWatch | $1.50 Billion USD |
| marketcap.company | $1.50 Billion USD |
| Reuters | $1.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.